Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
| Market Cap | $3.35B+75.6% |
| Revenue (ttm) | $0+100.0% |
| Net Income | -$163.19M-9.3% |
| EPS | -$1.42+21.1% |
| Shares Out | 128.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Mar 28, 2018 |
| Volume | 1,135,931 |
| Open | $25.64 |
| Previous Close | $26.20 |
| Day's Range | $25.52 - $26.40 |
| 52-Week Range | $10.83 - $41.14 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $49.29(+89.43%) |
| Earnings Date | Mar 2, 2027 |
About AMLX
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating AMLX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 2, 2027Earnings report
$AMLX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AMLX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AMLX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AMLX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AMLX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AMLX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AMLX
| VTIVanguard Morningstar Total Stock Market ETF | $86.67M |
| IWMiShares Russell 2000 ETF | $72.44M |
| VXFVanguard Extended Market ETF | $33.60M |
| IWOiShares Russell 2000 Growth ETF | $25.63M |
| IBBiShares Biotechnology ETF | $21.42M |
| VTWOVanguard Russell 2000 ETF | $17.58M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AMLX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive Phase 3 trial results and analyst price target increase outweigh valuation concerns raised in opinion pieces.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 25Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 2.45% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.84% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.61% |
| PEPT | REX Peptide ETF | 1.59% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.66% |
| FNY | First Trust Mid Cap Growth AlphaDEX Fund | 0.62% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 0.53% |
| FSCC | Federated Hermes MDT Small Cap Core ETF | 0.51% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.44% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.37% |
| FSML | Franklin Small Cap Enhanced ETF | 0.31% |
| ESSC | Eventide Small Cap ETF | 0.28% |
Weight is the stock’s share of each fund’s holdings.
